Related Experiment Video

Updated: May 31, 2026

Enhancing the Development and Growth of Infant Cerebral Palsy Rats Using Selective Spinal Manipulations
05:04

Enhancing the Development and Growth of Infant Cerebral Palsy Rats Using Selective Spinal Manipulations

Published on: February 2, 2024

Treatment of infantile spasms: emerging insights from clinical and basic science perspectives

Carl E Stafstrom1, Barry G W Arnason, Tallie Z Baram

  • 1University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53705, USA. stafstrom@neurology.wisc.edu

Journal of Child Neurology
|July 2, 2011
PubMed

Insights

Adrenocorticotropic hormone (ACTH) shows promise for treating infantile spasms, a severe infant epilepsy. This review explores potential mechanisms of ACTH action to improve therapeutic strategies.

Area of Science:

  • Neurology
  • Pediatric Neurology
  • Epileptology

Background:

  • Infantile spasms (IS) is a severe epileptic encephalopathy in early infancy.
  • IS has distinct clinical and EEG features, limited treatment options, and poor prognosis.
  • Lack of experimental models hinders development of improved IS therapies.

Purpose of the Study:

  • To review emerging candidate mechanisms underlying the therapeutic effects of adrenocorticotropic hormone (ACTH) in infantile spasms.
  • To provide an overview of current IS treatments and novel therapeutic approaches.
  • To discuss remaining clinical challenges and research questions in IS.

Main Methods:

  • This review synthesizes information from a specialist meeting on infantile spasms.
  • It examines existing literature on ACTH and infantile spasms.
  • Candidate mechanisms for ACTH's therapeutic effects are described.

Main Results:

  • Adrenocorticotropic hormone (ACTH) is an effective treatment for many infantile spasms cases.
  • The precise mechanisms of ACTH action in IS remain largely unknown.
  • Emerging research suggests potential pathways for ACTH's therapeutic benefits.

Conclusions:

  • Understanding ACTH's mechanism of action is crucial for improving infantile spasms treatment.
  • Further research into novel therapeutic approaches and experimental models is needed.
  • Addressing clinical challenges remains a priority for better IS patient outcomes.

More Related Videos

Repeated Transcranial Magnetic Stimulation Combined with Action Observation Training in Children with Spastic Cerebral Palsy07:20

Repeated Transcranial Magnetic Stimulation Combined with Action Observation Training in Children with Spastic Cerebral Palsy

Published on: August 9, 2024

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Related Concept Videos

Spasmolytic Agents: Chemical Classification01:29

Spasmolytic Agents: Chemical Classification

Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also promote...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
Centrally Acting Muscle Relaxants: Therapeutic Uses01:24

Centrally Acting Muscle Relaxants: Therapeutic Uses

Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Tetanus01:29

Tetanus

Tetanus is a life-threatening neurological disorder characterized by persistent muscle contractions and spastic paralysis. It is caused by Clostridium tetani, a motile, Gram-positive, rod-shaped, obligate anaerobe. These bacteria produce terminal endospores, giving them a distinctive “lollipop” or “tennis-racket” appearance. They thrive in anaerobic environments, such as those found in deep puncture wounds.Once introduced into the body, the spores germinate into vegetative cells. These cells...
Classification of Skeletal Muscle Relaxants01:28

Classification of Skeletal Muscle Relaxants

Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...